A recent study demonstrated that the knockout of the transcription factor AT-rich interactive domain-containing protein 3A (ARID3A) can inhibit tumor progression in pancreatic cancer and enhance the sensitivity of cells to gemcitabine. The gene discussed is ARID3A; the disease is pancreatic neoplasm.